Novo Nordisk, FDA Score Win in Weight Loss Drug Shortage Fight

The FDA lawfully determined that Novo Nordisk A/S’s ozempic drug shortage ended and that drug compounders can’t keep making copies of the weight loss medicine, a federal judge ruled.

Judge Mark T. Pittman for the US District Court for the Northern District of Texas agreed with the Food and Drug Administration that it lawfully removed semaglutide from the drug shortage list last year, granting on June 13 the agency’s motion for summary judgment against compounders.

The opinion is currently sealed but will eventually be redacted, according to the court’s docket.

The Outsourcing Facilities Association and compounding pharmacy FarmaKeio ...